You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
In this Research Topic, we would like to honor the memory of Prof. Vito Pistoia and pay tribute to his scientific contributions to the field of Cancer Immunity and Immunotherapy. Topic Editor Daniel Olive is the co-founder and shareholder of company Imcheck Therapeutics. All other topic editors declare no competing interests with regards to the Research Topic subject.
This Research Topic is the second volume in this series, "Community Series in Primary Immunodeficiencies Worldwide". Please see volume I here. Primary Immunodeficiencies are a group of approximately 300 diseases characterized by recurrent or chronic infections, autoimmunity, allergy, or inflammation as a consequence of genetic alterations affecting the immune system. The overall incidence is around 1:10,000 and they are more prevalent in children. According to the IUIS, primary immunodeficiencies are classified in 8 groups: combined immunodeficiencies; predominantly antibody deficiencies; diseases of immune dysregulation; congenital defects of phagocyte number, function, or both; defects in ...
Recognition and killing of aberrant, infected or tumor targets by Natural Killer (NK) cells is mediated by positive signals transduced by activating receptors upon engagement of ligands on target surface. These stimulatory pathways are counterbalanced by inhibitory receptors that raise NK cell activation threshold through negative antagonist signals. While regulatory effects are necessary for physiologic control of autoimmune aggression, they may restrain the ability of NK cells to activate against disease. Overcoming this barrier to immune surveillance, multiple approaches to enhance NK-mediated responses are being investigated since two decades. Propelled by considerable advances in the un...
None
None